Tilray Brands, Inc. Q1FY27 Earnings Call - TILRAY BRANDS INC

Financial Performance:

• Q1 2027 (ended Aug 31, 2026) revenue reached a record $257.1 million, a 23% year-over-year increase.
• Record first-quarter gross profit of $77.5 million, with consolidated gross margin expanding 300 basis points to 30%.
• International cannabis revenue grew 21% YoY; beverage revenue surged 82% to $101.5 million, driven by BrewDog integration.
• Cannabis gross margin improved 300 basis points YoY to 39%; beverage gross margin expanded to 41%.
• Reported a net loss of $40 million; adjusted net loss narrowed to $3 million (excluding non-cash/recurring items).
• Adjusted EBITDA was $9.2 million, impacted by $8.8 million in international price compression and $1.7 million in fuel surcharges.
• Balance sheet strengthened with $221 million in cash and marketable securities; $36 million in debt principal retired ($24M in quarter, $12M post-quarter).

Guidance and Future Outlook:

• Reaffirmed full-year 2027 adjusted EBITDA guidance of $68 million to $75 million despite seasonal headwinds.
• Projected Portugal facility to reach >40 metric tons of flower capacity in fiscal 2027, lowering unit costs significantly.
• Anticipated significant margin expansion from EU GMP facility utilization and integration efficiencies in the second half of the year.
• Carlsberg partnership expected to deliver immediate scale revenue contributions starting January 1, 2027, with evolving long-term growth.
• Long-term goal to leverage diversified platform to absorb SG&A costs, enabling scaling up to an additional $500M–$1B in sales.

Business Segments and Product Lines:

• Beverage: BrewDog returned to profitability in Q2 (post-Q1) following stabilization, cost rationalization, and new marketing campaigns ("Under New Ownership"); launched 8 new on-trade partnerships and secured 9,000+ new distribution points.
• Cannabis: Prioritized profitable growth over volume in Canada; diverted ~1 metric ton of inventory to higher-return international markets; Canada market share in THC beverages stands at >40%.
• Distribution: CC Pharma revenue grew 14% to $84.3 million with >16,000 pharmacy network access in Europe; margins improved YoY excluding one-time classification differences.
• U.S. Beer: Brand portfolio rationalization (selling off smaller breweries) and focus on core brands (Montauk, Sweetwater) led to market share gains (e.g., #2 craft vendor in Georgia/West); 28,000 on-premise accounts.
• Wellness: Manitoba Harvest revenue stable at $15.3 million; growth hindered temporarily by organic hemp seed supply constraints.

Market and Competitive Landscape:

• Tilray operates as the world's largest cannabis grower with 6M sq. ft. capacity and a low-cost production base in Canada and Portugal.
• In the UK, holds #1 spot for craft beer suppliers and #4 for total beer category; U.S. beer presence strong in regional markets (e.g., #3 craft brand in Georgia).
• International expansion focus includes Germany (Apria RX at 100% capacity), UK (Life direct-to-patient), and emerging markets like Australia, New Zealand, and the Middle East.
• Strategic partnership with Carlsberg Group validates Tilray's brewing capabilities and expands access to premium European brands in the U.S.

Risks and Challenges:

• Pricing Pressure: International cannabis markets face price compression (estimated $8.8M impact in Q1), though offset by margin expansion and volume growth.
• Regulatory Uncertainty: U.S. federal cannabis reform delays continue to impact sentiment; reliance on potential hemp beverage legal carve-outs in the U.S.
• Operational Headwinds: Fuel surcharges and inflation affecting input costs; temporary supply constraints for organic hemp seeds.
• Market Structure: Complex three-tier distribution system in the U.S. beer market poses challenges for direct-to-consumer/channel optimization.

Management Commentary and Tone:

• CEO Erwin Simon emphasized a shift from a single-category cannabis play to a diversified global platform across cannabis, beverage, wellness, and pharma distribution.
• Tone was confident and defensive regarding market perceptions, stressing that Tilray is not dependent on U.S. regulatory catalysts for growth.
• Management highlighted the strategic value of "scale" in absorbing high fixed costs (IT, insurance, R&D) inherent in the cannabis industry.
• Emphasized disciplined capital allocation, focusing on organic growth, cost control, and selective M&A rather than broad diversification without synergy.

Analyst Questions and Answers:

• International Cannabis: Confirmed that Tilray has excess capacity (Gatineau, Portugal, Germany) and a robust distribution network via CC Pharma, mitigating concerns over market consolidation.
• Beverage Margins: Explained margin recovery through brewery consolidation (reducing footprint to 5-6 facilities), supply chain efficiencies (hops, cans), and direct commercial engagement with major retailers (Kroger, Walmart).
• Carlsberg Partnership: No specific revenue figures disclosed, but described as a profit-sharing venture where Tilray produces and distributes Carlsberg's full U.S. portfolio; potential for cross-promotion and future expansion into other markets.
• M&A Strategy: While continuing to grow core cannabis and beverage operations, management remains open to acquisitions that offer complementary overhead sharing and infrastructure synergy.
• Germany Reimbursement: Majority of business is cash-pay for flower; oil reimbursement changes for new patients expected to have limited overall impact.
• THC Beverages in U.S.: Management anticipates a potential extension of hemp legality and possible milligram thresholds in the new Congress, positioning to launch quickly if approved.

Other Key Points:

• Tilray now operates nearly 40 hospitality venues (pubs, bars, hotels) globally, serving as a consumer engagement platform and data source.
• The company pays over $100 million CAD in excise taxes in Canada, viewing government revenue needs as a driver for expanded cannabis beverage access.
• BrewDog's "Choose Craft" campaign saw Punk IPA sales up 187% in top UK off-trade retailers within two weeks of launch.
• Management reiterated readiness to capitalize on U.S. cannabis reform, hemp beverage legalization, or global market expansion regardless of regulatory timelines.